Vetstem v. Innovations MedSpa: Stem Cell Patent Suit Dismissed With Prejudice
Vetstem, Inc. sued Innovations MedSpa, P.A. in the Northern District of Texas asserting two patents covering novel stem cell compositions and preparation methods. The case ended by joint stipulation of dismissal with prejudice after 301 days — a timeline consistent with pre-trial resolution.
Stem cell IP dispute ends by joint dismissal with prejudice in N.D. Tex.
Vetstem, Inc. filed suit against Innovations MedSpa, P.A. on January 12, 2024 in the Northern District of Texas (Fort Worth Division) before Judge Mark Pittman. The complaint asserted infringement of US9453202B2 and US11129855B2, both directed to methods of preparing and using novel stem cell compositions and associated kit formats — a technically specialised patent portfolio at the intersection of regenerative medicine and aesthetic or clinical spa services.
The case closed on November 8, 2024, when the court entered final judgment pursuant to Rule 58(a) giving effect to the parties’ Joint Stipulation of Dismissal with prejudice. A dismissal with prejudice is a final adjudication on the merits under federal procedural law, meaning Vetstem is barred from reasserting these specific infringement claims against Innovations MedSpa in any future action. The joint nature of the stipulation strongly suggests the parties reached a negotiated resolution — potentially a licensing agreement or a covenant not to sue — though the precise commercial terms are not disclosed in the public record.
At 301 days from filing to closure, the case resolved considerably faster than the multi-year trajectory common in fully litigated patent matters, suggesting that substantive settlement negotiations commenced early. What drove that timeline — whether claim construction exposure, financial constraints on either party, or a commercial deal — remains unknown from the public docket. The involvement of two defence firms (Bryan Cave Leighton Paisner and Ciccarelli Law Firm) alongside Vetstem’s specialist IP counsel at Friedman Suder & Cooke indicates both sides deployed significant litigation resources before resolution.
Filing to Case Dismissed in 301 days
301 days — faster than the median N.D. Tex. patent case, suggesting early resolution
Dismissed with prejudice by joint stipulation: what the ruling means
Joint stipulation with prejudice is a final, consensual end to litigation
Under Federal Rule of Civil Procedure 41(a)(1)(A)(ii), parties may jointly stipulate to dismiss a case. When entered with prejudice, the dismissal operates as a final judgment on the merits. The court here issued formal judgment under Rule 58(a), confirming the dismissal’s preclusive effect. No further litigation between these parties on the same claims is permissible.
Rule 41 joint stipulationVetstem forecloses re-litigation but likely secured a negotiated resolution
By accepting dismissal with prejudice, Vetstem permanently surrenders the right to sue Innovations MedSpa again on US9453202B2 and US11129855B2 for the conduct alleged. However, the joint nature of the stipulation is consistent with a confidential licensing deal or covenant not to sue — outcomes that would represent a commercial win even if no judgment was entered. The patents themselves remain valid and enforceable against other parties.
Patents remain enforceableInnovations MedSpa exits litigation with full finality on these claims
For Innovations MedSpa, a with-prejudice dismissal provides the strongest possible closure short of a court ruling on the merits. Vetstem cannot revive these specific claims. If the resolution included a licence, Innovations MedSpa would also gain certainty over ongoing operations involving the patented methods. The deployment of two law firms — Bryan Cave Leighton Paisner and Ciccarelli Law Firm — suggests the defendant treated the threat seriously from the outset.
Full claim finality securedStem cell IP enforcement signals growing risk for MedSpa and regenerative clinic operators
This case suggests that holders of regenerative medicine patents — particularly those covering stem cell preparation and administration methods — are actively monitoring commercial clinical settings such as medical spas. Operators offering adipose or similar stem cell therapies should treat this litigation as a signal to review their procedures against patents like US9453202B2. The speed of resolution may reflect the asymmetric litigation economics faced by smaller clinical operators.
Enforcement risk for MedSpa sectorFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Vetstem, Inc. | Company | Regenerative medicine company — holder of US9453202B2 and US11129855B2Search in Eureka ↗ |
| Defendant | Innovations MedSpa, P.A. | Individual | Medical spa operator accused of infringing stem cell composition and method patentsSearch in Eureka ↗ |
| Plaintiff counsel | Glenn S. Orman | Attorney | Counsel for Vetstem, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jonathan T. Suder | Attorney | Counsel for Vetstem, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Richard A Wojcio | Attorney | Counsel for Vetstem, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Friedman Suder & Cooke PC | Law Firm | Representing Vetstem, Inc.Search in Eureka ↗ |
| Defendant counsel | Brooke Valerie Ingoglia | Attorney | Counsel for Innovations MedSpa, P.A.Search in Eureka ↗ |
| Defendant counsel | Erin A. Kelly | Attorney | Counsel for Innovations MedSpa, P.A.Search in Eureka ↗ |
| Defendant counsel | Kenneth Lee Marshall | Attorney | Counsel for Innovations MedSpa, P.A.Search in Eureka ↗ |
| Defendant counsel | Max Ciccarelli | Attorney | Counsel for Innovations MedSpa, P.A.Search in Eureka ↗ |
| Defendant law firm | Bryan Cave Leighton Paisner LLP | Law Firm | Representing Innovations MedSpa, P.A.Search in Eureka ↗ |
| Defendant law firm | Ciccarelli Law Firm | Law Firm | Representing Innovations MedSpa, P.A.Search in Eureka ↗ |
| Presiding judge | Judge Mark Pittman | Judge | Texas Northern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s final judgment adopts the parties’ joint stipulation verbatim, confirming dismissal with prejudice under Rule 58(a). The phrase ‘in accordance with the Parties’ Joint Stipulation’ indicates no contested adjudication of validity or infringement — the court made no finding on the merits. For Vetstem, claim preclusion now bars re-litigation of these specific allegations; for Innovations MedSpa, the prejudicial dismissal provides permanent finality on the asserted claims, though it leaves the underlying patents intact and enforceable against third parties.
US9453202B2 & US11129855B2 — Stem Cell Compositions and Methods
US9453202B2 (application no. US10/575063) and US11129855B2 (application no. US16/859790) both protect innovations in stem cell composition preparation and application, including kit-based formats. The subject matter sits within the regenerative medicine field — specifically the isolation, preparation, and therapeutic use of stem cell populations, a domain that spans veterinary and human clinical applications. US11129855B2, with its later application number, likely represents a continuation or improvement on the foundational technology covered by the earlier patent.
For the regenerative medicine sector, patents of this type carry strategic significance well beyond traditional pharmaceutical channels. As stem cell therapies migrate into aesthetic medicine, sports recovery, and medical spa settings, patent holders controlling foundational method and composition claims acquire leverage over an expanding commercial ecosystem. Vetstem’s decision to assert both patents simultaneously suggests the portfolio is designed to provide overlapping claim coverage, making design-arounds more difficult for commercial operators and downstream kit suppliers.
Should you run an FTO analysis against US9453202B2 and US11129855B2?
Any commercial operator — MedSpa, regenerative clinic, or kit manufacturer — involved in the preparation or administration of stem cell compositions should treat these patents as priority FTO targets. The asserted product description (‘methods of preparing and using novel stem cell compositions and kits comprising the same’) is broad enough to implicate a wide range of adipose-derived or stromal-vascular-fraction procedures offered in clinical and aesthetic settings. The fact that Vetstem filed suit against a single MedSpa operator in federal court signals active enforcement intent.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of US9453202B2 and US11129855B2 against your specific protocols, product labelling, and preparation workflows. By identifying claim elements that overlap with your commercial activities, Eureka helps R&D and legal teams prioritise design-around opportunities, document non-infringing alternatives, and build a defensible FTO opinion — before a demand letter arrives.
Run a freedom-to-operate analysis on US9453202B2 to assess your product’s exposure
Run FTO in Eureka →Similar stem cell and regenerative medicine patent cases in U.S. federal courts
Explore related patent infringement actions involving stem cell compositions, regenerative medicine methods, and therapeutic kits litigated in U.S. district courts.
What this case signals for the regenerative medicine IP landscape
Stem cell patent enforcement is expanding beyond pharma labs into commercial clinical settings. MedSpa and regenerative clinic operators face real exposure.
MedSpa operators offering stem cell therapies face credible patent infringement risk
Vetstem’s willingness to file suit in federal court against a single medical spa operator signals a deliberate enforcement strategy targeting commercial clinical users of stem cell methods. Operators who have not conducted FTO analysis on their cell preparation and administration protocols should do so now — particularly where adipose-derived or similar stem cell procedures are offered.
Joint with-prejudice dismissals often conceal licensing deals — monitor for follow-on suits
When a plaintiff accepts a with-prejudice joint dismissal, the most commercially rational explanation is a licensing arrangement. If Vetstem is building a licensing programme around US9453202B2 and US11129855B2, other MedSpa and regenerative medicine clinic defendants should anticipate demand letters. The 301-day resolution timeline suggests this pathway may be the plaintiff’s preferred enforcement model.
Vetstem v Innovations — key questions answered
Vetstem, Inc. filed a patent infringement action against Innovations MedSpa, P.A. in the Northern District of Texas on January 12, 2024, asserting US9453202B2 and US11129855B2 covering stem cell compositions and preparation methods. The case was dismissed with prejudice by joint stipulation on November 8, 2024, after 301 days — consistent with a negotiated resolution, though specific terms are not disclosed in the public record.
Vetstem asserted two patents: US9453202B2 and US11129855B2. Both are directed to methods of preparing and using novel stem cell compositions and kits. US9453202B2 corresponds to application US10/575063 and US11129855B2 to application US16/859790. Together they provide overlapping claim coverage across composition, method, and kit aspects of stem cell technology.
A dismissal with prejudice operates as a final judgment on the merits under federal law. The plaintiff — here, Vetstem — is permanently barred from refiling the same infringement claims against the same defendant for the same conduct. The underlying patents remain valid and enforceable against other parties. In patent cases, a joint with-prejudice stipulation is often, though not always, consistent with a confidential licensing or settlement agreement.
The public record does not disclose Vetstem’s specific enforcement rationale. However, the patents asserted cover methods of preparing and using stem cell compositions — procedures increasingly offered in commercial medical spa and aesthetic clinic settings. The suit is consistent with a patent enforcement or licensing programme targeting commercial clinical operators who deploy stem cell preparation methods covered by the asserted claims.
Vetstem was represented by Glenn S. Orman, Jonathan T. Suder, and Richard A. Wojcio of Friedman Suder & Cooke PC. Innovations MedSpa was represented by Brooke Valerie Ingoglia, Erin A. Kelly, and Kenneth Lee Marshall of Bryan Cave Leighton Paisner LLP, and Max Ciccarelli of Ciccarelli Law Firm. The defendant’s engagement of two law firms suggests the respondent deployed substantial litigation resources in response to the suit.
PatSnap Eureka searches patents and litigation data to answer instantly.